Inogen Reports Q3 2026 Results with Revenue Decline Amid International Market Softness
Inogen (INGN) reported third-quarter revenue of $77.2 million, a 2.4% year-over-year decrease driven by a 9% decline in international sales. While U.S. sales grew by 3.8% to $42.2 million due to distributor demand and new respiratory products, softness in European markets and inventory management issues weighed on the overall top line. The company reported an adjusted net loss of $400,000 compared to a profit in the prior year. The company is currently undergoing a strategic transition toward a leaner operating model following the divestiture of its U.S. oxygen rental business, which is expected to yield up to $24.8 million in cash by early 2027. Management is focusing on cost management, targeting $20 million in annualized savings by the end of 2027 through organizational simplification and SG&A efficiencies.
Tickers: $INGN
Topics: Gross Margin International Sales Operating Expenses Product Growth Revenue U.S. Sales